# SARS-CoV-2 infection of BNT162b2(mRNA)-vaccinated individuals is not restricted to variants of concern or high-risk exposure environments

Brittany Rife Magalis 1,2, Carla Mavian 1,2, Massimiliano Tagliamonte 1,2, Shannan N. Rich 1,3,4, Melanie Cash 1,2, Alberto Riva 5, Julia C. Loeb 1,6, Michael Norris 1,6, David Moraga Amador 5, Yanping Zhang 5, Jerne Shapiro 3,4, Petr Starostik 2, Simone Marini 1,3, Paul Myers 4, David Ostrov 2, John A. Lednicky 1,6, J. Glenn Morris Jr. 1, Michael Lauzardo 1,4,7, Marco Salemi 1,2,[$],

1Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA, 32610

2Department of Pathology, University of Florida, Gainesville, FL, USA, 32610

3Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, FL, USA, 32610

4Florida Department of Health, Alachua County, Gainesville, FL, USA, 32641

5Interdisciplinary Center for Biotechnology Research, Gainesville, FL, USA, 32610

6Department of Environmental and Global Health, University of Florida, Gainesville, Florida 32610

7Division of Infectious Diseases and Global Medicine, College of Medicine, University of Florida, Gainesville, FL, USA, 32610

[$]Corresponding author

**Abstract**

The emergence of SARS-CoV-2 variants of concern (VOC) has raised questions regarding the extent of protection of currently implemented vaccines. Ten “vaccination breakthrough” infections were identified in Alachua County, Florida, among individuals fully vaccinated with the BNT162b2 mRNA vaccine as a result of social or household transmission. Eight individuals

presented mild symptoms in the absence of infection with other common respiratory viruses, confirmed using viral genetic sequencing. SARS-CoV-2 genomes were successfully generated for five of the vaccine breakthroughs and 399 individuals in the surrounding area and were included for reference-based phylogenetic investigation. These five individuals were characterized by infection with both VOCs and low-frequency variants present within the surrounding population. Mutations, in the Spike glycoprotein, were consistent with their respective circulating lineages. However, we detected an additional mutation in Spike's N-terminal domain of a B.1.1.7 strain, present at low-frequency (~1%) in the unvaccinated population, potentially affecting protein's stability and functionality. The findings highlight the critical need for continued testing and monitoring of infection among individuals regardless of vaccination status.

Several rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have risen to the status of "variants of concern" (VOC), according to the Centers for Disease Control (CDC, https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html), accumulating as many as 17 unique genomic mutations with respect to the original viral strain originating from the Wuhan province of China (1). These VOCs include the lineages most notably defined by their area of origin, such as the United Kingdom (UK). The UK VOC, also referred to as the B.1.1.7 lineage using the Pango nomenclature (2), emerged in September of 2020 in Kent, UK, but quickly made its way to the United States (US, (3)). More recently, the B.1.427/B.1.429 lineages, two forms collectively dubbed the "California variant", were added to the CDC's list of VOCs, as they have spread widely since their initial detection in July of 2020 in Los Angeles County, California (4). The emergence of these and other VOCs, and their level of evolutionary divergence from the original strain, has raised questions regarding the extent of protection of currently implemented vaccines against infection (5-8). Here, we report epidemiological and genomic data (where available) for vaccination

53 breakthrough cases from Alachua County, Florida, in the context of the diverse SARS-CoV-2
54 epidemic in Florida and the remaining US.

55

56 **Results**

57 From January to March 2021, Alachua County, Florida, experienced a reduced number of
58 infections (~11% drop in % positive cases), with a general increase in number of vaccinations,
59 particularly since the last week of February (**Figure S1**). Regardless of the reduced coronavirus
60 disease (COVID-19) burden in the county, continued testing of vaccinated individuals has
61 provided insight into susceptibility of vaccines to circulating viral variants within the region.
62 Between February and March 2021, ten individuals enrolled in the UF Health Screen, Test &
63 Protect (STP) program (**online Methods**) tested positive using the standard polymerase chain
64 reaction (PCR)-based assay for SARS-CoV-2 infection after completing the BNT162b2 mRNA
65 two-dose vaccine series (9). Individuals were considered fully vaccinated two weeks after their
66 second vaccination in a 2-dose series. By March 17, 2021, more than 59,000 individuals were
67 vaccinated with at least one dose of one of Pfizer (49%), Moderna (49%), or Johnson &
68 Johnson (2%) vaccines in Alachua County, Florida (10). The number of infections among
69 vaccinated individuals suggests a relatively low breakthrough rate consistent with the high
70 efficacy of Pfizer's BNT162b2 vaccine demonstrated in clinical trials (9), though it is important to
71 acknowledge the small sample size of this study and potential sampling biases incorporated in
72 the STP program that limit drawing any conclusions regarding validation of efficacy (**online**
73 **Methods**). The ten "vaccine-breakthrough" individuals were all identified within 27-47
74 (mean=37.6) days following the second dose, eight of which presented with symptoms
75 characteristic of COVID-19 **(Tables 1** and **S1**). The majority of these individuals identified as
76 female (90%), White (80%), under the age of 35 (mean=34), and reported their occupation as
77 healthcare-related (80%), including students working in patient care. Contact tracing revealed

78 that seven of these individuals had exposures to individuals previously identified as COVID-19
79 cases in the two weeks prior to their disease onset, with four reporting the nature of the
80 relationship as household and three as community/social. None of the individuals reported
81 exposure in the workplace. So, despite healthcare workers increased risk of exposure, infection
82 in these individuals was likely the result of inadvertent exposure during social contact.

83

84 Secondary saliva samples were collected from the ten vaccine-breakthrough individuals within
85 3-7 days of testing positive for infection (**Tables 1** and **S1**). Saliva collection was used in this
86 study for the isolation of viral RNA, as this bodily fluid has demonstrated prolonged presence of
87 viral RNA (up to 25 days post-symptom onset, (11)), irrespective of disease severity (12). The
88 research protocol (**online Methods**) was approved by the University of Florida institutional
89 review board. SARS-CoV-2 full-genome (>70%) sequences were successfully generated for
90 five of the vaccinated individuals. A panel of additional respiratory viruses was also targeted
91 during sequencing (**Table S2**), confirming the absence in all patients of additional infection with
92 common viruses, such as influenza. Thus, clinical symptoms, when present, were likely the
93 result of productive coronavirus infection. The reason for insufficient SARS-CoV-2 genome
94 quality for five of the vaccine breakthrough cases is not fully clear. Results from COVID-19
95 testing for the majority of these individuals were limited to qualitative data (positive or negative),
96 though the number of PCR cycles (Cq) required for reliable viral RNA amplification for two of the
97 individuals were provided and already >25 at the time of diagnosis (**Table S3**), which has been
98 considered relatively high for genomic sequencing (13). Given the time between diagnosis and
99 saliva sampling (**Table S1**), saliva viral load may have been too low for the genomic
100 amplification required for amplicon-based sequencing for some individuals. While mutations in
101 primer-binding regions can reduce genome coverage for amplicon-based sequencing (13),
102 coverage mapping did not indicate this phenomenon – alternating regions of high- and low-

103 coverage were not observed (**Figure S2**). Two of these individuals were, however,
104 asymptomatic whereas asymptomatic individuals were not found among the successful full-
105 genome sequences (**Table S2**), supporting the link between severity of symptoms and rapidity
106 of viral clearance (14).
107
108 In order to understand the context of the vaccine breakthrough infections, we assembled a full-
109 genome sequence dataset (n=3902) including sequences generated from hospital samples in
110 Alachua County between January-March 2021 (n=399), all Floridian sequences (n=3,016)
111 deposited into the GISAID database (https://gisaid.org), and epidemiologically relevant
112 sequences from the global population (also from GISAID). Epidemiological relevance was
113 defined on an individual sequence basis, restricting the global GISAID search to the two
114 sequences most similar genetically to each Floridian sequence and sampled within a high-
115 confidence transmission time window (30 days) based on sample collection date. Additional
116 details on this method (termed "FLACO-BLAST") can be found in the **online Methods** and (15),
117 and the script is available from https://github.com/salemilab/flaco. GISAID IDs and
118 corresponding submission information are provided in **Table S4**. Owing to low genetic
119 variability, as well as potentially shared epidemiological linkages, sequences retrieved from
120 GISAID were often shared by more than one query (Florida) sequence, resulting in a total of
121 482 non-Floridian sequences, all of which were located within the US. The resulting dataset
122 spanned October 10, 2020 to March 17, 2021.
123
124 Lineages for all sequences were determined using the PangoLEARN model (Pangolin v 2.3.6),
125 which was trained using ~60,000 GISAID SARS-CoV-2 sequences to classify incoming
126 sequences based on molecular and epidemiological criteria (2). The full dataset in this study
127 was characterized by a total of 106 lineages, for which only nine (B.1.X) lineages
128 represented >99% of samples (**Figure 1A**). The distribution of lineages for Floridian sequences

129 outside of Alachua County largely resembled that of the non-Floridian reference sequences, as
130 expected given the filtering approach for genetic similarity described above; the exception to this
131 similarity was the presence of the B.1.375 lineage within the Florida dataset, which was not
132 present among reference sequences (**Figure 1A**). As this lineage was not observed among the
133 Alachua County sequences, further investigation into the potential misclassification of these
134 sequences as the B.1.375 lineage, more notably associated with the northern states (16), was
135 considered outside the scope of this study. Whereas both the Alachua County and remaining
136 Floridian samples were dominated by the B.1.234 lineage in November 2020, both regions
137 quickly expanded to include at least seven other lineages by mid-January 2021 (**Figure 1A**).
138 This expansion included a growing presence of the B.1.1.7 (or UK VOC) and B.1.427 (California
139 VOC) lineages (**Figure 1A**). Given the growth in the UK and California variants within the
140 Florida population, it is not surprising that three of the vaccinated individuals reported in this
141 study were determined to belong to these VOCs – 1 B.1.1.7 and 2 B.1.247/B.1.249. The
142 remaining two vaccinated individuals, however, presented with the high-frequency (~16%) B.1
143 lineage and low-frequency (<1%) B.1.377 lineage, neither of which is considered a VOC.
144
145 Following lineage classification, a maximum likelihood phylogenetic tree was reconstructed from
146 the sequences in order to verify lineage classification and to determine relationships among
147 vaccinated individuals in the context of geographical and temporal information (**Figure 1B**).
148 Bootstrap replicates for the sequence data were used to provide support for branching patterns
149 within the tree (17-19), and the smallest (number of sequences), well-supported (>90% of
150 replicates) clade involving each vaccination-breakthrough case was examined individually.
151 Whereas four of the five successfully sequenced, vaccinated individuals belonged to relatively
152 small, definable clades (**Figure 1C-D**), reliable placement of the fifth B.1-lineage individual
153 within the tree could not be obtained, despite >90% coverage of the genome (**Figure S2**). This
154 sequence did, however, share common ancestry with similarly B.1 sequences, supporting

155 proper lineage assignment (**Figure S3**). The two individuals harboring the B.1.429 California
156 VOC belonged to a clade of 20 individuals comprised of additional B.1.429/B.1.427 variants,
157 confirming lineage classification using Pangolin (**Figure 1C**). The remaining 18 sequences
158 within this clade consisted primarily of Floridian sequences (nine from Alachua County), with the
159 exception of one individual from Minnesota, suggesting largely local transmission of this variant,
160 though directionality of transmission cannot be inferred. The two vaccine-breakthrough cases
161 with the B.1.429 VOC in this study (STP-413 and STP-412) reported separate exposures; the
162 two individuals were also not more closely related to each other phylogenetically than the
163 remainder of the sequences (with significant support), so we can neither confirm nor exclude the
164 possibility of a relationship via direct transmission between these two individuals specifically.
165
166 Circulation of the other VOC in the US, B.1.1.7, has been defined as the result of at least two
167 separate introductions (3). One introduction was estimated to occur early November, 2020, into
168 California, and was characterized by a virus resembling more closely the traditional UK variant.
169 The second introduction, estimated to occur in late November, carried a silent mutation from
170 cytosine to thymine within the ORF1ab gene encoding the RNA-dependent RNA polymerase
171 (position 15720 relative to genome start). The expanding virus populations originating from
172 these two events were referred to as “Clade 1” and “Clade 2.” Approximately 13% of B.1.1.7
173 individuals within the total Florida sample, and 86% of B.1.1.7 in Alachua County, harbored the
174 “Clade 2” C15720T mutation, including the vaccine-breakthrough case. This individual (STP-11)
175 belonged to a well-supported clade in this study comprised of five total individuals (**Figure 1D**),
176 all sharing the B.1.1.7 lineage designation (again confirming pangolin classification) and “Clade
177 2” mutation. Despite the prevalence of the “Clade 2” mutation among B.1.1.7 individuals in
178 Alachua County, only one other sample within the vaccine-breakthrough clade originated from
179 the county. The remaining four samples were collected in Pennsylvania, New York, and New

180 Jersey, consistent with the earlier evidence of a more widespread presence of this B.1.1.7
181 variant within the US (3). The individual was reportedly exposed to a recent COVID-19 case
182 outside of the household. Contact tracing of this individuals' exposed contacts did not identify
183 any secondary cases associated with this vaccine failure, and so the question of ongoing
184 transmission following infection in this individual remains unanswered.
185
186 The final clade containing the low-frequency B.1.377 vaccinated individual (STP-410) shared
187 significant common ancestry with a single Floridian B.1.377 sequence, confirming lineage
188 classification and suggesting transmission within Florida, but not confined to the county (**Figure**
189 **1E**).
190
191 Even though infection in fully vaccinated individuals does not appear to be related to the viral
192 variant, mutational analysis was necessary to determine if 1) recently acquired mutations (i.e.,
193 not conserved among the corresponding lineage) could potentially be responsible for limited
194 protection of the vaccine against infection or 2) evidence exists for the emergence of vaccine-
195 resistant variants. The viral protein commonly referred to as the Spike protein is structurally
196 important for coronaviruses, rendering it susceptible to recognition by the host immune
197 response, specifically the receptor-binding domain (RBD). For this reason, vaccination efforts
198 have largely focused on this region of the genome (9, 20, 21), though there is evidence that the
199 host immune system can also target the N-terminal domain (NTD, (22, 23)). The natural
200 accumulation of mutations in these regions owing to the error-prone viral replication machinery
201 can lead to the ability of the virus to evade the host immune response, including that of
202 vaccinated individuals, and may be responsible for enhanced transmissibility of the variant (24).
203 The B.1.429 and B.1.377 variants found within three of the breakthrough-vaccinated individuals
204 did not appear to have acquired any additional Spike mutations outside of those associated with
205 the parental lineage, suggesting newly acquired mutations were not responsible for

206 breakthrough infections and that this individual did not harbor a vaccine-resistant variant.
207 However, two mutations relative to the parental B.1.1.7 lineage (1) were observed within the
208 Spike protein for the B.1.1.7 vaccinated individual – L18F and K1191N within the NTD and C-
209 terminal domain (CTD) of the Spike protein, respectively (**Figure 2A,** corresponding to positions
210 within the reference sequence MN908947). The HR2 K1191N mutation was present in ~75% of
211 samples for Alachua County, ~75% of the remainder of Florida samples, and ~75% of US
212 reference sequences, suggesting a less recent acquisition of this mutation in the population and
213 no relation to vaccine-mediated adaptation or an enhanced ability to infect vaccinated
214 individuals. Alternatively, the NTD L18F mutation was far less prevalent, only observed in 16
215 individuals from Florida (dating back to January 15, 2021), but not from the Alachua County
216 area (**Figure 2B**). It was known that the B.1.1.7 vaccination-breakthrough individual (STP-11)
217 was exposed to an infected individual from Orange County, Florida, which suggests a regional
218 Florida outbreak with this particular mutation that spilled over into Alachua County. No evidence
219 of secondary cases associated with this individual again cannot confirm ongoing transmission of
220 this variant among vaccinated individuals, though this mutation may warrant further investigation
221 for its antigenic properties and relationship to vaccination efficacy.
222
223 Several molecular vaccine and/or antigenic studies in the context of the B.1.1.7 variant have
224 focused on the RBD, demonstrating no significant effect on neutralization of the virus (25) and
225 no loss of affinity for host antibodies (Abs) to the RBD when compared to the original strain.
226 Meanwhile, mutations in the NTD (other than L18F) have been proposed to alter Ab affinity,
227 potentially paving the way for infection in vaccinated individuals (20). The structural
228 consequence of the recently acquired NTD L18F mutation indicates that this Floridian B.1.1.7
229 variant may be a variant of concern. In addition to B.1.1.7 deletions that eliminate antigenic
230 epitopes for neutralizing antibodies (26) and T cells (Δ69-70, Δ144), this variant exhibits an
231 amino acid change with the potential to stabilize the NTD of the Spike protein. Amino acid

232 position 18 is located within the N1 loop (residues 14 to 26), wherein the original L (Lysine) is
233 oriented towards F (Phenylalanine) at position 79 of the N2 loop (residues 67 to 79, **Figure 3A**).
234 The change from L to F in the Florida B.1.1.7 variant is predicted to form stabilizing contacts
235 between F18 in the N1 loop and S252 in the N5 loop (residues 246 to 260) (**Figure 3B**). These
236 data suggest that the Floridian B.1.1.7 variant found in the B.1.1.7 vaccinated individual may
237 exhibit a fitness advantage that results from increased stability and functionality of the NTD.
238
239 In order to verify viability of this new mutation, infectivity of the virus isolated from individual
240 STP-11 was measured *in vitro* (**online Methods**). Positive infection, and thus viability, was
241 defined by the presence of virus-specific cytopathic effects (CPE) on Vero E6 cells (African
242 green monkey kidney cells). CPE were first noted 12 days post-inoculation (dpi), primarily
243 consisting of rounding of cells, some in the process of detaching from the growing surface
244 (**Figure 4**). Quantification of virus at 12 dpi for the STP-11 sample-infected cells and control (no
245 viral inoculation) confirmed viral replication ($C_q$ 8.14 and $C_q$ > 39, respectively).
246
247 **Discussion**
248 A recent study in Israel reported that vaccinated individuals were disproportionally infected with
249 VOCs relative to the unvaccinated population (27). Whereas we cannot exclude the impact of
250 prevalence of VOCs within the Florida population on their rate of breakthrough, the findings of
251 our study, collectively with (27), indicate limited protection of the BNT162b2 mRNA vaccine (and
252 potentially others) against emerging variants of SARS-CoV-2. It is important to note that none of
253 the breakthrough individuals in this study was hospitalized, corroborating the vaccine's 100%
254 efficacy against severe disease (9). While these individuals presented with only mild symptoms
255 (or no symptoms at all), the number of vaccine breakthrough cases might be expected to be
256 under-reported. Hence, if we assume at least a minority of test-positive vaccinated individuals
257 harbor infectious virus, the potential for hidden reservoirs within the global populations is

258 increased. Hidden reservoirs in asymptomatic or mild symptomatic individuals, as has been
259 proposed (15), pose a particular threat to early recognition of mutations of potential concern,
260 such as the L18F mutation described herein, particularly once vaccination is more widespread.
261 Moreover, given the effectiveness of the vaccine in limiting symptom presentation, vaccinated
262 individuals may engage more frequently in social activities, increasing the risk of exposure.
263 Continued testing and case management, assessing contacts and exposure, for vaccinated
264 individuals is thus encouraged and will be forthcoming in determining whether the vaccine is
265 protective against ongoing evolution and spread of SARS-CoV-2. This strategy is particularly
266 important in the face of relaxed guidelines regarding masked protection and social distancing for
267 vaccinated individuals, declared by the CDC as of May, 2021.
268

269 **Acknowledgments**

270 This work was supported by the Stephany W. Holloway University of Florida Chair and by funds
271 of the University of Florida Office of Research and Health Science Center with resources from
272 the Interdisciplinary Center for Biotechnology Research Gene Expression Core
273 (RRID:SCR_019145), NextGen Sequencing Core (RRID:SCR_019152) and Bioinformatics Core
274 (RRID:SCR_019120). Funding for this work was also provided by National Science Foundation
275 (NSF) – Division Of Environmental Biology (DEB) award no. 2028221.
276
277

278 **Table 1. Reported cases of vaccination breakthroughs in Alachua County, Florida.**

| **Characteristic** | |
|---|---|
| **Age (years)** | 34.0 (15.0) |
| **Sex** | |
| Female | 9 (90.0%) |
| **Race** | |
| White | 8 (80.0%) |
| Ethnicity | |
| **Hispanic** | 2 (20.0%) |

| | |
|---|---|
| **Symptoms (Y)** | 8 (80.0%) |
| Cough | 1 (12.5%) |
| Anosmia | 1 (12.5%) |
| Sore throat | 3 (37.5%) |
| Headache | 4 (50.0%) |
| Runny nose | 5 (62.5%) |
| Fatigue | 2 (25.0%) |
| **Comorbidities** | |
| Asthma | 1 (10.0%) |
| **BMI** | 24.6 (5.0) |
| **Known exposure (Y)** | 7 (70.0%) |
| Household | 4 (57.1%) |
| Community | 3 (42.9%) |
| **Occupation** | |
| Healthcare worker | 7 (70.0%) |
| Student engaged in patient care | 2 (20%) |
| Unemployed | 1 (10%) |
| **Time between second vaccination dose and disease onset (days)** | 37.6 (21.3) |
| **Time between disease onset (for symptomatic cases) and sample collection date (days)** | 5.0 (2.0) |

*Results are presented as frequency (%) for categorical variables and mean (standard deviation) for continuous variables.




**Figure 1. Distribution of identified lineages and geographical origin of sampling over time (A) and within the phylogenetic tree (B-D) of SARS-CoV-2 data collected from Florida and relevant non-Florida locations.** (A) Lineage (as identified using Pangolin (2) distribution over time for Alachua County, the surrounding Florida areas, and locations outside of Florida linked to Florida sequences via genetic similarity. (B) Distribution of both assigned lineages and geographic origin (as in (A)) across the maximum likelihood phylogenetic tree. Branches are scaled in genetic substitutions/site, and nodes with ≥90% support using bootstrap sampling are indicated by grey dots. Vaccinated individuals within well-supported clades have been emphasized, and corresponding clades are represented as insets in panels C-D. *Other lineages, defined as present within <1% of the total sample population.




**Figure 2. Mutational profiles for vaccine-breakthrough individuals (A) and comparison of B.1.1.7 individuals with remaining sequence data (B).** Mutations in red are present in vaccinated individual (VAC), but not fixed in the parental lineage. Spike protein architecture is displayed at the top of both panels, wherein S = spike subunit (1-2); NTD = N-terminal domain; CTD (1-3) = C-terminal domain; RBD = receptor binding domain; PRRA = SARS-CoV-2 characteristic PRRA insertion at the $S_1/S_2$ cleavage site; FP = fusion peptide; HR (1-2) heptad repeat. Positions numbers are relative to the Spike protein in the MN908947 reference sequence.




**Figure 3. Potential stabilizing effect of Floridian B.1.1.7 variant mutation from Lysine (A) to Phenylalanine (B) at position 18 of the Spike protein N-terminal domain (NTD).** Loops N1, N2, and N5 of the NTD are represented in green, pink, and blue, respectively. Modified interactions as a result of the mutation are represented as dotted lines, with original L18 oriented toward position F79 (cyan) of the N1 loop (A), and the variant F18 toward S252 of the N5 loop (B), potentially acting to stabilize. Dotted lines represent distances 3.8 (A) and 3.6 (B) Angstrom. Positions numbers are relative to the Spike protein in the MN908947 reference sequence.




**Figure 4. Cytopathic effects in Vero E6 cells inoculated with saliva sample FL-STP-Saliva-11**. (A) Mock-infected Vero E6 cells, 12 dpi. (B) Early SARS-CoV-2-specific CPE, 12 dpi. Rounded cells, some in the process of detaching from the growth surface, are pointed out by yellow arrows. Original magnification at 400X.

319 **Methods**

320

321 **Participant involvement and sample processing.** UF Health Screen, Test & Protect (STP)
322 assists the Florida Department of Health in Alachua County with COVID-19 case and contact
323 tracing efforts in its UF students, faculty, staff and other UF-affiliated people including the UF
324 Health Academic Medical Center (~123,000 total UF Affiliates). Full epidemiological
325 investigations were conducted on positive cases to collect exposure information, trace contacts,
326 and provide disease transmission education. Fully vaccinated individuals who became a contact
327 (defined as ≥15min and closer than 6 feet) were called and provided public health education but
328 not placed into quarantine. For 14 days after their last exposure, they received a daily text or
329 email to record symptom development. Immediate PCR testing was recommended for anyone
330 newly reporting symptoms and day 7 PCR testing was recommended for all fully vaccinated but
331 exposed individuals, regardless of symptom development. Individuals working in health care
332 settings may have been sampled more frequently due to internal hospital policies.

333 Fully vaccinated UF affiliates deemed PCR-positive for SARS-CoV-2 were eligible for molecular
334 epidemiology investigation as part of the STP program if they met the following criteria:

335 1) The case must be infectious at the time of saliva sample donation. Infectiousness was
336 defined ≤10 days after the onset of symptoms or for an asymptomatic individual ≤10 days after
337 the positive lab collection date.

338 2) The case must meet the definition of a vaccine-breakthrough case. Defined as PCR-
339 positive for SARS-CoV-2 and ≥14 days after the second dose of Pfizer or Moderna.

340 If both criteria were met and individuals volunteered to provide a sample for the purpose of
341 public health molecular surveillance, they were scheduled to arrive on-site for sample collection
342 as soon as possible to increase the probability of detectable virus at the time of collection. Each

343 participant was asked to give a saliva sample of at least 2 mL in total volume and was instructed
344 not to drink anything for 10 minutes prior to giving the sample. The saliva was collected in a 15
345 mL conical tube, filling it to the 2 mL marking on the tube, not including froth. Patient samples
346 were de-identified following Institutional Review Board approval before viral processing. Viral
347 RNA was extracted from 180 uL of each saliva sample using the QIAamp 96 Viral RNA Kit with
348 the QIAcube HT (Qiagen, Germantown, MD) using the following settings with a filter plate: the
349 lysed sample was premixed 8 times before subjecting to vacuum for 5 minutes at 25kP and
350 vacuum for 3 min at 70kPa. Following 3 washes using the same vacuum conditions above, the
351 samples were eluted in 100 uL AVE buffer followed by a final vacuum for 6 minutes at 60kPa.
352 Nine microliters of RNA was used for cDNA synthesis and library preparation using the
353 COVIDSeq Test kit (Illumina, San Diego, CA) and Mosquito HV Genomics Liquid Handler (SPT
354 Labtech Inc., Boston MA). The size and purity of the library was determined using the 4200
355 TapeStation System (Agilent, Santa Clara, CA) and the Qubit dsDNA HS Assay Kit (Life
356 Technologies, Carlsbad, CA) according to the manufacturer's instructions. Constructed libraries
357 were pooled and sequenced using the NovaSeq 6000 Sequencing System SP Reagent Kit and
358 the NovaSeq Xp 2-Lane Kit. Illumina's DRAGEN pipeline was used to derive sample
359 consensus sequences, which were filtered based on a minimum of 70% coverage of the
360 genome.

361

362 **Database sequence retrieval.** Each Floridian sequence was used in a local alignment (BLAST)
363 (28) search for the most (genetically) similar non-Floridian sequence in the GISAID database as
364 of March 23, 2021, and linked to two reference sequences including the best match (highest E-
365 value) with a date occurring within one month following, as well as one month prior to the
366 sampling date of the Floridian sequence (15). After removing duplicate sequences (sequences
367 with same GISAID ID), sequences were aligned in viralMSA (29) using the MN908947 reference

368 sequence, and mutations potentially associated with contamination, recurrent sequencing
369 errors, or hypermutability were masked using a vcf filter (https://virological.org/t/masking-
370 strategies-for-sars-cov-2-alignments/480).
371
372 **Cell culture for viral infectivity.** Vero E6 cells were used for SARS-CoV-2 isolation attempts.
373 The cells had been obtained from the American Type Culture Collection (catalog no. ATCC
374 CRL-1586) and have been used for our SARS-CoV-2 projects (30-33), including the isolation
375 of > 30 SARS-CoV-2 isolates from human and environmental samples. The cells were
376 propagated in cell culture medium comprised of aDMEM (advanced Dulbecco's modified
377 essential medium, Invitrogen, Carlsbad, CA) supplemented with 10% low antibody, heat-
378 inactivated, gamma-irradiated fetal bovine serum (FBS, Hyclone, GE Healthcare Life Sciences,
379 Pittsburgh, PA), L-alanine, L-glutamine dipeptide supplement (GlutaMAX,), and 50 µg/mL
380 penicillin, 50 µg/mL streptomycin, 100 µg/mL neomycin (PSN antibiotics, Invitrogen) with
381 incubation at 37°C in 5% $CO_2$.
382
383 **Isolation of virus in cultured cells.** Virus isolation attempts were performed in a BSL3
384 laboratory at the University of Florida Emerging Pathogens Institute (EPI) by analysts who wore
385 powered air-purifying respirators and engaged in BSL3 work practices. Vero E6 cells grown as
386 monolayers in a T-25 flask (growing surface 25 $cm^2$) were inoculated when they were at 80% of
387 confluency as follows: for each flask, the spent cell culture medium was removed and replaced
388 with 1 mL of supplemented aDMEM medium ("complete medium") with 10% FBS, and the cells
389 inoculated with 50 µL of unfiltered saliva. Prior to inoculation, samples were frozen (-80°C)
390 within 15 minutes following collection. Samples were only thawed once to produce an aliquot for
391 processing. The inoculated cell cultures were incubated at 37°C in 5% $CO_2$, and rocked every
392 15 minutes for 1 hour, after which 4 mL of complete medium with 10% FBS was added. The
393 following day, the cell culture media was completely removed and replenished with 5 mL of

394 maintenance medium (complete medium with 3% FBS). Mock-infected cell cultures were
395 maintained in parallel with the other cultures. The cell cultures were refed every 3 days by the
396 replacement of 2 mL of spent media with maintenance medium. The cells were observed daily
397 for one month before being judged negative for virus isolation, with a blind passage performed
398 15 days post-inoculation of the cells. When virus-induced cytopathic effects (CPE) were evident,
399 the presence of SARS-CoV-2 in the cell culture medium was examined by real-time reverse
400 transcription PCR (rRT-PCR). In the event that SARS-CoV-2 strains that were not cytolytic or
401 did not produce CPE had been isolated, the culture media were blindly tested at weekly
402 intervals.
403
404 **Detection of SARS-CoV-2 genomic RNA (vRNA) in cell culture medium.** vRNA was
405 extracted from virions in collection media in a Class II biosafety cabinet in a BSL3 laboratory at
406 the EPI by analysts wearing appropriate personal protective equipment (chemically impervious
407 Tyvek lab coats and gloves) and using powered-air purifying respirators. The vRNA was
408 extracted from 140 µL aliquots of the collection media using a QIAamp Viral RNA Mini Kit
409 (Qiagen, Valencia, CA, USA), and purified RNA eluted from the RNA-binding silicon column in a
410 volume of 80 µL. Twenty-five µL (final volume) rRT-PCR tests were performed in a BioRad
411 CFX96 Touch Real-Time PCR Detection System using 5 µL of purified vRNA and the N1 and
412 N2 primers and their corresponding probes of the CDC 2019-Novel Coronavirus (2019-nCoV)
413 rtRT-PCR test (34). The primers and probes were purchased from Integrated DNA
414 Technologies (IDT, Coralville, Iowa, USA). A plasmid that encodes the SARS-CoV-2 N-gene
415 sequence was purchased from IDT and used in positive control reactions for the CDC N1 and
416 N2.
417 The rRT-PCR tests were performed using the following parameters: 400 nM final
418 concentration of forward and reverse primers and 100 nM final concentration of probe using a
419 SuperScript III One-Step RT-PCR system with Platinum Taq DNA Polymerase (ThermoFisher

420 Scientific). Cycling conditions were 20 minutes at 50°C for reverse transcription, followed by 2
421 minutes at 95°C for Taq polymerase activation, then 45 cycles of denaturation for 15 seconds at
422 95°C, annealing for 30 seconds at 55°C, and extension at 68°C for 20 seconds.
423
424 **Table S1. Sample and sequencing information for vaccinated (VAC) individuals.**

| VAC-ID | Time between second vaccination dose and disease onset[a] (days) | Time between onset[b] and sample collection (days) | Symptom status | Exposure | Lineage |
|---|---|---|---|---|---|
| STP-Saliva-11 | 31 | 4 | Symptomatic | Community | B.1.1.7 |
| STP-Saliva-410 | 36 | 6 | Symptomatic | Household | B.1.377 |
| STP-Saliva-409 | 32 | 4 | Symptomatic | Household | Undetermined |
| STP-Saliva-412 | 37 | 6 | Symptomatic | Community | B.1.429 |
| STP-Saliva-413 | 35 | 7 | Symptomatic | Household | B.1.429 |
| STP-Saliva-411 | 47 | 3 | Asymptomatic | Household | Undetermined |
| STP-Saliva-512 | 27 | 5 | Symptomatic | Unknown | Undetermined |
| STP-Saliva-511 | 51 | 1 | Asymptomatic | Unknown | Undetermined |
| STP-Saliva-514 | 39 | 7 | Symptomatic | Community | Undetermined |
| STP-Saliva-513 | 41 | 7 | Symptomatic | Unknown | B.1 |

425 [a]Onset implies the date of symptom onset for symptomatic individuals or the date of lab collection for the
426 result of virus detection among asymptomatic individuals.
427
428 **Table S2. Respiratory virus coverage during sequencing of saliva samples from vaccine-**
429 **breakthrough individuals.**

| VAC-ID | Virus | Total Coverage[a] | Median Coverage[b] |
|---|---|---|---|
| STP-Saliva-11 | Influenza B virus (B/Brisbane/60/2008) | 17369 | 0 |
| | Influenza A virus (A/Michigan/45/2015(H1N1)) | 2368 | 0 |
| | Influenza B virus (B/Wisconsin/01/2010) | 1352 | 0 |
| | Influenza A virus (A/Texas/50/2012(H3N2)) | 874 | 0 |
| | Influenza B virus (B/Washington/02/2019) | 50 | 0 |
| STP-Saliva-409 | Influenza B virus (B/Brisbane/60/2008) | 843 | 0 |
| | Influenza A virus (A/Michigan/45/2015(H1N1)) | 139 | 0 |
| | Influenza A virus (A/Texas/50/2012(H3N2)) | 27 | 0 |
| | Influenza B virus (B/Wisconsin/01/2010) | 24 | 0 |
| | Influenza B virus (B/Lee/1940) | 12 | 0 |
| STP-Saliva-410 | Influenza B virus (B/Brisbane/60/2008) | 9748 | 0 |
| | Influenza A virus (A/Michigan/45/2015(H1N1)) | 1310 | 0 |
| | Influenza A virus (A/Texas/50/2012(H3N2)) | 656 | 0 |
| | Influenza B virus (B/Wisconsin/01/2010) | 480 | 0 |
| | Human coronavirus HKU1 | 88 | 0 |

| | | | |
|---|---|---|---|
| | Influenza B virus (B/Washington/02/2019) | 57 | 0 |
| | Human coronavirus NL63 | 35 | 0 |
| | Human adenovirus B1 | 27 | 0 |
| | Human adenovirus E4 | 14 | 0 |
| | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | 12 | 0 |
| STP-Saliva-411 | Influenza B virus (B/Brisbane/60/2008) | 801 | 0 |
| | Influenza A virus (A/Michigan/45/2015(H1N1)) | 109 | 0 |
| | Influenza A virus (A/Texas/50/2012(H3N2)) | 79 | 0 |
| | Influenza B virus (B/Wisconsin/01/2010) | 26 | 0 |
| | Human adenovirus B1 | 23 | 0 |
| | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | 12 | 0 |
| STP-Saliva-412 | Influenza B virus (B/Brisbane/60/2008) | 14738 | 0 |
| | Influenza A virus (A/Michigan/45/2015(H1N1)) | 2055 | 0 |
| | Influenza A virus (A/Texas/50/2012(H3N2)) | 1447 | 0 |
| | Influenza B virus (B/Wisconsin/01/2010) | 1065 | 0 |
| | Influenza B virus (B/Washington/02/2019) | 54 | 0 |
| | Human adenovirus C2 | 35 | 0 |
| | Influenza B virus (B/Lee/1940) | 13 | 0 |
| STP-Saliva-413 | Influenza A virus (A/Michigan/45/2015(H1N1)) | 6848 | 0 |
| | Influenza B virus (B/Brisbane/60/2008) | 5036 | 0 |
| | Influenza A virus (A/Texas/50/2012(H3N2)) | 306 | 0 |
| | Influenza B virus (B/Wisconsin/01/2010) | 241 | 0 |
| | Human adenovirus C2 | 36 | 0 |
| | Human coronavirus NL63 | 25 | 0 |
| | Human metapneumovirus (CAN97-83) | 24 | 0 |
| | Human adenovirus E4 | 22 | 0 |
| | Human parainfluenza virus 3 | 13 | 0 |
| | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | 12 | 0 |
| STP-Saliva-511 | Influenza B virus (B/Brisbane/60/2008) | 1269 | 0 |
| | Influenza A virus (A/Michigan/45/2015(H1N1)) | 168 | 0 |
| | Influenza A virus (A/Texas/50/2012(H3N2)) | 62 | 0 |
| STP-Saliva-512 | Influenza B virus (B/Brisbane/60/2008) | 133 | 0 |
| | Influenza B virus (B/Wisconsin/01/2010) | 87 | 0 |
| | Influenza A virus (A/Michigan/45/2015(H1N1)) | 51 | 0 |
| | Human adenovirus C2 | 12 | 0 |
| | Human adenovirus B1 | 12 | 0 |
| | Human bocavirus 4 NI strain HBoV4-NI-385 | 12 | 0 |

| | | | |
|---|---|---|---|
| STP-Saliva-513 | Influenza B virus (B/Brisbane/60/2008) | 5498 | 0 |
| | Influenza A virus (A/Michigan/45/2015(H1N1)) | 1550 | 0 |
| | Influenza A virus (A/Texas/50/2012(H3N2)) | 551 | 0 |
| | Influenza B virus (B/Wisconsin/01/2010) | 330 | 0 |
| | Influenza B virus (B/Washington/02/2019) | 39 | 0 |
| | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | 12 | 0 |
| | Human adenovirus B1 | 12 | 0 |
| STP-Saliva-514 | Human adenovirus C2 | 111 | 0 |
| | Respiratory syncytial virus (type A) | 24 | 0 |
| | Influenza B virus (B/Lee/1940) | 13 | 0 |
| | KI polyomavirus Stockholm 60 | 13 | 0 |
| | Influenza B virus (B/Wisconsin/01/2010) | 13 | 0 |

[a]Total number of bases observed for viral (partial) target using COVIDSeq Test kit (Illumina, San Diego, CA)
[b]Coverage per base within viral (partial) target using COVIDSeq Test kit (Illumina, San Diego, CA)

**Table S3. Quantification results from initial detection of SARS-CoV-2 (at time of diatnosis) in vaccinated individuals**

| VAC-ID | Cq[ab] |
|---|---|
| STP-Saliva-11[b] | Not available |
| STP-Saliva-410[b] | Not available |
| STP-Saliva-409[b] | Not available |
| STP-Saliva-412[b] | Not available |
| STP-Saliva-413[b] | Not available |
| STP-Saliva-513[b] | Not available |
| STP-Saliva-411 | Not available |
| STP-Saliva-512 | Not available |
| STP-Saliva-511 | 36.48 CT |
| STP-Saliva-514 | 28.85 CT |

[a]PCR quantification cycle
[c]Vaccinated individuals with 70% genome coverage at 50x sequencing coverage/site.
*

## Table S2. GISAID author acknowledgment table.

We gratefully acknowledge the following Authors from the Originating laboratories responsible for obtaining the specimens, as well as the Submitting laboratories where the genome data were generated and shared via GISAID, on which this research is based.

All Submitters of data may be contacted directly via www.gisaid.org

Authors are sorted alphabetically.

| Accession ID | Originating Laboratory | Submitting Laboratory | Authors |
|---|---|---|---|
| EPI_ISL_1225879, EPI_ISL_1226183, EPI_ISL_1226188 | "AK State Public Health Lab, State Health Department" | Genomics and Discovery, Respiratory Viruses Branch, Division of Viral Diseases, Centers for Disease Control and Prevention | Anna Montmayeur; Anna Uehara; Ben L. Rambo-Martin; Clinton R. Paden; Dhwani Batra; Haibin Wang; Jasmine Padilla; Jing Zhang; Justin Lee; Katie Dillon; Krista Queen; Kristen Knipe; Kristine Lacek; Lori Rowe; Mark Burroughs; Matthew Schmerer; Mili Sheth; Peter W. Cook; Rachel Marine; Sam Shepard; Sarah Nobles; Shoshona Le; Suxiang Tong; Yan Li; Ying Tao |
| EPI_ISL_1226332, EPI_ISL_1226338 | "OK Public Health Laboratory, Oklahoma State DOH" | Genomics and Discovery, Respiratory Viruses Branch, Division of Viral Diseases, Centers for Disease Control and Prevention | Anna Montmayeur; Anna Uehara; Ben L. Rambo-Martin; Clinton R. Paden; Dhwani Batra; Haibin Wang; Jasmine Padilla; Jing Zhang; Justin Lee; Katie Dillon; Krista Queen; Kristen Knipe; Kristine Lacek; Lori Rowe; Mark Burroughs; Matthew Schmerer; Mili Sheth; Peter W. Cook; Rachel Marine; Sam Shepard; Sarah Nobles; Shoshona Le; Suxiang Tong; Yan Li; Ying Tao |
| EPI_ISL_699655 | 1-Laboratory of Microbiology, National Reference Lab, Charles Nicolle Hospital; 2-University of Tunis ElManar, Faculty of Medicine of Tunis, LR99ES09, Tunis, Tunisia | 1-Clinical and Experimental Pharmacology Lab, LR16SP02, National Center of Pharmacovigilance, University of Tunis El Manar, Tunis, Tunisia. 2-Neurodegenerative diseases and psychiatric troubles, LR18SP03, Razi Hospital, University of Tunis El Manar, Tunis, Tunisia. 3- Ministry of Health, National Observatory of New and Emerging Diseases, 1006, Tunis, Tunisia | Alia Ben Kahla; Asma Ferjani; Gaies Emna; Guedi Berrabeh; Hanen ElJebari; Ilhem Boutiba-Ben Boubaker; Jalila Ben Khelil; Maher Kharrat; Mouna Ben Sassi; Mouna Safer; Nissaf Ben Alaya; Riadh Daghfous; Riadh Gouider.; Salma Abid; Salwa Mrabet; Sameh Trabelsi; Sana Ferjani |
| EPI_ISL_1013566 | 1.AO Universitaria 'S. Giovanni di Dio e Ruggi D'Aragona, Scuola Medica Salernitana' Hospital / 2.UOC di Virologia e Microbiologia, Università della Campania 'L. Vanvitelli' / 3.AO Universitaria 'Federico II' Napoli Hospital / 4.AORN 'San Giuseppe Moscati' Avellino Hospital / 5.AO 'San Pio - presidio G. Rummo' Benevento Hospital / 6.AO 'Sant'Anna e San Sebastiano' Caserta Hospital / 7.PO 'Maria Santissima Addolorata' Eboli Hospital / 8.Biogem Istituto di Ricerche Genetiche | 1. Genome Research Center for Health (CRGS) / 2. Laboratory of Molecular Medicine and Genomics(LMMGe) / 3. Center for Research in Pure and Applied Mathematics (CRMPA) | Alessandro Weisz; Alessia Cossu; Andreina Baj; Aniello Gentile; Annamaria Salvati; Antonello Saccomanno; Arnolfo Petruzziello; Assunta Sellitto; Carlo Ferravante; Domenico Memoli; Domenico Palumbo; Edmondo Adorisio; Elena Alexandrova; Emilia Vaccaro; Fausto Sessa.; Francesca Marciano; Francesca Rizzo; Francesco Curcio; Gianluigi Franci; Giorgio Dirani; Giorgio Giurato; Giovanni Nassa; Giovanni Pecoraro; Giuseppe Fenza; Giuseppe Portella; Gregorio Goffredi; Ilaria Terenzi; Jessica Lamberti; Maddalena Schioppa; Maria Grazia Foti; Maria Landi; Marianna Scrima; Mariarosaria Ingino; Massimiliano Galdiero; Maurizio Fumi; Michela Iacobellis; Michele Caraglia; Michele Cennamo; Morena D'Avenia; Oriana Strianese; Pasquale Pagliano; Rita Greco; Roberta Tarallo; Rosanna Piluscio; Silvia Zanoli; Simona Semprini; Sonia Amabile; Stefania Marzinotto; Teresa Rocco; Valeria Mirici Cappa; Vincenzo Rocco; Viola Melone; Vittoria Letizia; Vittorio Sambri; Ylenia D'Agostino |
| EPI_ISL_982502 | ADIRONDACK MEDICAL CENTER | Wadsworth Center, New York State Department of Health | Alexis Russel; Daryl M. Lamson; Erasmus Schneider; Erica Lasek-Nesselquist; John Kelly; Jonathan Plitnick; Kirsten St. George; Matthew Shudt; Melissa A Leisner; Navjot Singh |
| EPI_ISL_1095229 | AK State Public Health Lab, State Health Department | Respiratory Viruses Branch, Division of Viral Diseases, Centers for Disease Control and Prevention | Anna Montmayeur; Anna Uehara; Ben L. Rambo-Martin; Clinton R. Paden; Dhwani Batra; Haibin Wang; Jasmine Padilla; Jing Zhang; Justin Lee; Krista Queen; Lori Rowe; Mark Burroughs; Mili Sheth; Peter W. Cook; Rachel Marine; Sarah Nobles; Suxiang Tong; Yan Li; Ying Tao |
| EPI_ISL_1094818 | AR Dept. of Health-Public Health Lab | Respiratory Viruses Branch, Division of Viral Diseases, Centers for Disease Control and Prevention | Anna Montmayeur; Anna Uehara; Ben L. Rambo-Martin; Clinton R. Paden; Dhwani Batra; Haibin Wang; Jasmine Padilla; Jing Zhang; Justin Lee; Krista Queen; Lori Rowe; Mark Burroughs; Mili Sheth; Peter W. Cook; Rachel Marine; Sarah Nobles; Suxiang Tong; Yan Li; Ying Tao |
| EPI_ISL_1166231, EPI_ISL_1166252 | ASL Napoli 1 Centro | AMES Centro Polidiagnostico Strumentale S.r.l. | "Giovanni Savarese; Antonella Di Carlo; Antonio Fico"; Eloisa Evangelista; Luigi D'Amore; Luisa Circelli; Maurizio D'Amora; Monica Ianniello; Nadia Petrillo; Raffaella Ruggiero; Roberto Sirica |
| EPI_ISL_1027445, EPI_ISL_1027467, EPI_ISL_1235463, EPI_ISL_1235476 | Alameda County Public Health Lab | Chan-Zuckerberg Biohub | CZB Cliahub Consortium |
| EPI_ISL_911688, EPI_ISL_1195922 | Alaska State Virology Laboratory | Alaska State Virology Laboratory | Elva House; Jack Chen; Lisa Smith; Ph.D.; Stephanie DeRonde |
| EPI_ISL_933583, EPI_ISL_933589, EPI_ISL_967882, EPI_ISL_978486, EPI_ISL_1016924, EPI_ISL_1064177, EPI_ISL_1184559, EPI_ISL_1239095 | | | |
| see above | Arizona State Public Health Laboratory | Arizona State Public Health Laboratory | Jessica Escobar; Katherine Fullerton; Linda Getsinger; Nobuko Fukushima; Stacy White; Trung Huynh; Victor Waddell |
| EPI_ISL_1118038 | Austrian Agency for Health and Food Safety (AGES) | Bergthaler laboratory, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences | Andreas Bergthaler; Anna Schedl; Bekir Erguner; Benedikt Agerer; Christoph Bock; Jan Laine; Lukas Endler; Maelle Le Moing; Martin Senekowitsch; Michael Schuster; Thomas Penz |
| EPI_ISL_884859 | Bacteriology, Georgia Public Health Laboratory (GPHL) | Bacteriology, Georgia Public Health Laboratory (GPHL) | Dixey, C.; Edwards, J.; Parrott, T.; Reeves, S. |
| EPI_ISL_1081181 | Baylor Scott & White-Temple | Baylor Scott & White-Temple | Ari Rao; Kimberly Walker; Linden Morales; Marcus Volz; Shelby Hendrickson |
| EPI_ISL_1049207 | Blackhawk Genomics | Pathogen Discovery, Respiratory Viruses Branch, Division of Viral Diseases, Centers for Disease Control and Prevention | Anna Uehara; Brian Lynch; Clinton R. Paden; Haibin Wang; Han Jia Ng; Jing Zhang; Krista Queen; Peter Cook; Suxiang Tong; Yan Li; Ying Tao |
| EPI_ISL_1121640, EPI_ISL_1253808, EPI_ISL_1253817 | Broad Institute Clinical Research Sequencing Platform | Infectious Disease Program, Broad Institute of Harvard and MIT | Adams, G.; B.L.; B.W.; Bauer, M.; Birren; Carter, A.; Chaluvadi, S.; D.J.; DeRuff, K.; Gallagher, G.; Gladden-Young, A.; J.E.; K.J.; Lagerborg, K.; Lemieux; Loreth, C.; MacInnis; Normandin, E.; P.C.; Park; Reilly, S.; Rudy, M.; Siddle; Smole, S.; Tomkins-Tinch, C.; and Sabeti |
| EPI_ISL_906885, EPI_ISL_906886, EPI_ISL_906887, EPI_ISL_906889, EPI_ISL_906891, EPI_ISL_906892, EPI_ISL_906894, EPI_ISL_906895, EPI_ISL_906897, EPI_ISL_906898, EPI_ISL_906899, EPI_ISL_906900, EPI_ISL_906903, EPI_ISL_906906, EPI_ISL_906908, EPI_ISL_906909, EPI_ISL_906913 | | | |
| see above | Bureau of Public Health Laboratories, Florida Department of Health (BPHL, FLDOH) | Bureau of Public Health Laboratories, Florida Department of Health (BPHL, FLDOH) | Blanton, J.; Schmedes, S. |
| EPI_ISL_1225957 | CA-Los Angeles County Public Health Laboratory | Genomics and Discovery, Respiratory Viruses Branch, Division of Viral Diseases, Centers for Disease Control and Prevention | Anna Montmayeur; Anna Uehara; Ben L. Rambo-Martin; Clinton R. Paden; Dhwani Batra; Haibin Wang; Jasmine Padilla; Jing Zhang; Justin Lee; Katie Dillon; Krista Queen; Kristen Knipe; Kristine Lacek; Lori Rowe; Mark Burroughs; Matthew Schmerer; Mili Sheth; Peter W. Cook; Rachel Marine; Sam Shepard; Sarah Nobles; Shoshona Le; Suxiang Tong; Yan Li; Ying Tao |
| EPI_ISL_1094478 | CT-Dr. Katherine A. Kelley State Public Health Lab | Respiratory Viruses Branch, Division of Viral Diseases, Centers for Disease Control and Prevention | Anna Montmayeur; Anna Uehara; Ben L. Rambo-Martin; Clinton R. Paden; Dhwani Batra; Haibin Wang; Jasmine Padilla; Jing Zhang; Justin Lee; Krista Queen; Lori Rowe; Mark Burroughs; Mili Sheth; Peter W. Cook; Rachel Marine; Sarah Nobles; Suxiang Tong; Yan Li; Ying Tao |
| EPI_ISL_847665 | California Department of Public Health | Chiu Laboratory, University of California, San Francisco | Brian Bushnell; Candace Wang; Charles Chiu; Debra Wadford; Jill Hacker; Scot Federman; Xianding (Wayne) Deng |
| EPI_ISL_824561, EPI_ISL_824679 | Cedars-Sinai Medical Center, Department of Pathology & Laboratory Medicine, Molecular Pathology Laboratory | Cedars-Sinai Medical Center, Molecular Pathology Laboratory of Department of Pathology & Laboratory Medicine and Genomic Core | Brian Davis; Eric Vail; Jasmine T Plummer; Jorge Mario Sincuir Martinez; Stephanie Chen; Wenjuan Zhang |
| EPI_ISL_1168655, EPI_ISL_1168671 | Centers for Disease Control and Prevention, Dengue Branch | Centers for Disease Control and Prevention, Dengue Branch | Betzabel Flores; Gabriela Paz-Bailey; Gilberto A. Santiago; Glenda Gonzalez; Jorge L. Munoz-Jordan; Keyla Charriez |
| EPI_ISL_961847 | Centrala laboratorija | Latvian Biomedical Research and Study Centre | Davids Fridmanis; Ivars Silamikelis; Jana Osite; Janis Pjalkovskis; Janis Klovins; Jurijs Perevoscikovs; Kaspars Megnis; Laila Silamikele; Lauma Freimane; Laura Ansone; Liga Birzniece; Marta Priedite; Monta Ustinova; Nikita Zrelovs; Uga Dumpis; Vita Rovite |
| EPI_ISL_978135, EPI_ISL_978137 | Chiu Laboratory, University of California, San Francisco | Chiu Laboratory, University of California, San Francisco | Candace Wang; Charles Chiu; Debra Wadford; Jill Hacker; Venice Servellita; Xianding (Wayne) Deng |
| EPI_ISL_1163754, EPI_ISL_1163791 | Clinical Molecular Microbiology Laboratory, UNC Hospital | Dirk Dittmer | Angelica Juarez; Blossom Damania.; Brent A. Eason; Cameroon Grant; Carolina Caro-Vegas; Cecilia Thompson; Dirk Dittmer; Evelyn Hoffman; Jason Wong; Justin T. Landis; Linda Pluta; Melissa B. Miller; Patricio Cano; Razia Moorad; Ryan McNamara; Shawn Hawken |
| EPI_ISL_861455, EPI_ISL_911598, | Clinical Molecular Microbiology Laboratory, UNC Hospitals | Jeremy Wang | Alexander Rubinsteyn; Colleen Rice; Corbin Jones; Jason Smedberg; Jeremy Wang; Melissa Miller; Robert Hagan; Shawn Hawken |




**Figure S1. COVID-19 vaccinations and test positivity in Alachua County, Florida, from January 1st – March 31st, 2021.**




**Figure S2. SARS-CoV-2 genome coverage for (A) five successfully and (B) five unsuccessfully sequenced vaccinated individuals.** Coverage in this plot refers to the number of reads representing each position within the MN908947 reference SARS-CoV-2 genome and was provided by Illumina.




**Figure S3. Distribution of identified lineages and geographical origin within a fragment of the phylogenetic tree containing FL-Shands-VTM-513 (B.1 lineage).** Branches shown are scaled in genetic substitutions/site. Nodes with ≥90% support using bootstrap sampling are indicated by grey dots. This clade is not well-supported but represents a fragment of the tree in Figure 1 three nodes back from the FL-STP-Saliva-513 taxon. Other lineages represent lineages comprising <1% of the total sample population, though in this subtree only B.1.349 and B.1.363 are present.

## References


1. Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virologicalorg. 2020;https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563.
2. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020;5(11):1403-7.

466 3. Larsen B, Worobey M. Phylogenetic evidence that B.1.1.7 has been circulating in the United
467 States since early- to mid-November. Virologicalorg. 2021(https://virological.org/t/phylogenetic-
468 evidence-that-b-1-1-7-has-been-circulating-in-the-united-states-since-early-to-mid-november/598).
469 4. Zhang W, Davis BD, Chen SS, Sincuir Martinez JM, Plummer JT, Vail E. Emergence of a Novel
470 SARS-CoV-2 Variant in Southern California. JAMA. 2021;325(13):1324-6.
471 5. Hitchings MDT, Ranzani OT, Scaramuzzini Torres MS, de Oliveira SB, Almiron M, Said R, et al.
472 Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-
473 negative case-control study. medRxiv. 2021:2021.04.07.21255081.
474 6. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1
475 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021.
476 7. Buss LF, Prete CA, Abrahim CMM, Mendrone A, Salomon T, de Almeida-Neto C, et al. Three-
477 quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic.
478 Science. 2021;371(6526):288-92.
479 8. Sabino BD, Alonso FOM, Oliveira MSC, Venceslau MT, Guimarães MAAM, Varella RB. Long-term
480 intermittent detection of SARS CoV 2 in the upper respiratory tract: what is the meaning of it? Infect Dis
481 (Lond). 2021;53(2):151-3.
482 9. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of
483 the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
484 10. Alachua County COVID-19 Recovery Dashboard https://dashboards.alachuacounty.us/COVID19/
485 [
486 11. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in
487 posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2:
488 an observational cohort study. Lancet Infect Dis. 2020;20(5):565-74.
489 12. Zhu J, Guo J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. J Infect.
490 2020;81(3):e48-e50.
491 13. Charre C, Ginevra C, Sabatier M, Regue H, Destras G, Brun S, et al. Evaluation of NGS-based
492 approaches for SARS-CoV-2 whole genome characterisation. Virus Evol. 2020;6(2):veaa075.
493 14. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV
494 viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-
495 analysis. Lancet Microbe. 2021;2(1):e13-e22.
496 15. Giovanetti M, Cella E, Benedetti F, Magalis BR, Fonseca V, Fabris S, et al. SARS-CoV-2 shifting
497 transmission dynamics and hidden reservoirs limited the efficacy of public health interventions in Italy.
498 medRxiv. 2020:2020.12.16.20248355.
499 16. Moreno G, Braun K, Larsen B, Alpert T, Worobey M, Grubaugh N, et al. Detection of non-B.1.1.7
500 Spike Δ69/70 sequences (B.1.375) in the United States. Virologicalorg.
501 2021 https://virological.org/t/detection-of-non-b-1-1-7-spike-69-70-sequences-b-1-375-in-the-united-
502 states/587.
503 17. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-
504 TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. Mol Biol Evol.
505 2020;37(5):1530-4.
506 18. Hoang DT, Chernomor O, von Haeseler A, Minh BQ, Vinh LS. UFBoot2: Improving the Ultrafast
507 Bootstrap Approximation. Mol Biol Evol. 2018;35(2):518-22.
508 19. Minh BQ, Nguyen MA, von Haeseler A. Ultrafast approximation for phylogenetic bootstrap. Mol
509 Biol Evol. 2013;30(5):1188-95.
510 20. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the
511 mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16.
512 21. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim Results of a
513 Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021.

514 22. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive
515 mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal
516 human plasma antibodies. Cell Host Microbe. 2021;29(3):463-76.e6.
517 23. Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, et al. Neutralizing and
518 protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike
519 protein. Cell. 2021.
520 24. Ostrov D. Structural consequences of variation in SARS-CoV-2 B.1.1. Scientific Archives.
521 2021;3(2):103-8.
522 25. Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, et al. Serum Neutralizing
523 Activity Elicited by mRNA-1273 Vaccine. N Engl J Med. 2021.
524 26. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants
525 B.1.351 and B.1.1.7. Nature. 2021.
526 27. Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, et al. Evidence for increased
527 breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals.
528 medRxiv. 2021:2021.04.06.21254882.
529 28. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol
530 Biol. 1990;215(3):403-10.
531 29. Moshiri N. ViralMSA: Massively scalable reference-guided multiple sequence alignment of viral
532 genomes. Bioinformatics. 2020.
533 30. Lednicky JA, Lauzardo M, Fan ZH, Jutla A, Tilly TB, Gangwar M, et al. Viable SARS-CoV-2 in the air
534 of a hospital room with COVID-19 patients. Int J Infect Dis. 2020;100:476-82.
535 31. Lednicky JA, Cherabuddi K, Tagliamonte MS, Elbadry MA, Subramaniam K, Waltzek TB, et al. In-
536 Frame 12-Nucleotide Deletion within Open Reading Frame 3a in a SARS-CoV-2 Strain Isolated from a
537 Patient Hospitalized with COVID-19. Microbiol Resour Announc. 2021;10(8).
538 32. Carbone M, Lednicky J, Xiao SY, Venditti M, Bucci E. Coronavirus 2019 Infectious Disease
539 Epidemic: Where We Are, What Can Be Done and Hope For. J Thorac Oncol. 2021;16(4):546-71.
540 33. Lednicky JA, Lauzardo M, Alam MM, Elbadry MA, Stephenson CJ, Gibson JC, et al. Isolation of
541 SARS-CoV-2 from the air in a car driven by a COVID patient with mild illness. Int J Infect Dis. 2021.
542 34. CDC. CDC real-time reverse transcriptase PCR (rRT-PCR) diagnostic test for COVID-19
543 https://www.cdc.gov/coronavirus/2019-ncov/lab/virus-requests.html [

544